Perseus Holdings USA Welcomes Ben "Bud" M. Brigham to Board of Directors
Perseus Holdings USA has appointed Ben "Bud" M. Brigham to its board of directors. Brigham, an experienced entrepreneur with a successful track record, has raised substantial capital and previously took companies public. He aims to leverage his expertise in corporate strategy and capital markets to support Perseus's advancements in immuno-oncology. Brigham's prior ventures include founding Brigham Exploration, which went public and was sold for $4.5 billion. His involvement is expected to enhance shareholder value and help progress Perseus's innovative cancer treatment technologies.
- Brigham's extensive experience in raising capital and driving company growth.
- Potential for enhanced shareholder value through Brigham's strategic insights.
- Expertise in corporate strategy may help advance Perseus's immuno-oncology efforts.
- Concerns may arise regarding the continuity and existing board dynamics with the new appointment.
AUSTIN, Texas, Sept. 15, 2020 /PRNewswire/ -- Perseus Holdings USA, an immuno-oncology company focused on the development and commercialization of next-generation, immune-mediated technologies for the treatment of cancer, today announced the appointment of Ben "Bud" M. Brigham to its board of directors, effective immediately. Mr. Brigham is a serial entrepreneur with approximately 30 years of executive experience, having founded several enterprises in the energy and real estate sectors, and has participated as an investor across a wide variety of industries. He currently serves as chairman of Anthem Ventures, Brigham Minerals (NYSE: MNRL), Atlas Sand and Brigham Exploration. Brigham Exploration is the namesake for the first company he founded in 1990, which went public in 1997 prior to its sale in 2011.
"We are thrilled for Mr. Brigham to join the board of directors. His experience as an entrepreneur and investor, having raised substantial capital, including successfully taking two companies public, and importantly his track of value creation for shareholders, will bring significant value to Perseus as we continue to advance our personalized therapeutic cancer vaccines through clinical research and into commercialization," said Buddy Long, chief executive officer of Perseus Holdings USA. "Bud brings a wealth of expertise in corporate strategy, finance, operational oversight, capital markets and investor relations, along with a unique skillset that will complement the board's vision for the organization."
"Perseus' innovative technology platform for advancing the field of immuno-oncology, experienced team and promising approach to revolutionizing the way cancers are treated is a compelling combination, and I'm very pleased to be joining this talented team at such an exciting time for the organization," said Mr. Brigham.
As founder and CEO of Brigham Exploration, Mr. Brigham managed the company's rapid growth as a private company from an initial investment of
About Perseus Holdings, LLC
Perseus Holdings USA, LLC is an immuno-oncology company focused on the development and commercialization of next-generation, immune-mediated technologies for the treatment of cancer. Elios Therapeutics, LLC, a wholly owned subsidiary of Perseus Holdings, LLC., is a biopharmaceutical company developing a portfolio of innovative personalized therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types.
Perseus holds executive licenses for Elios' lead therapeutic candidate, the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, a personalized therapeutic cancer vaccine that uses a proprietary particle delivery system to stimulate the body's immune system to recognize cancer cells as foreign pathogens and fight a patient's specific cancer. Perseus and its subsidiaries are investigating the clinical potential of TLPLDC in U.S. FDA clinical trials. For more information, please visit www.perseusholdingsusa.com.
Forward-Looking Statements
This document contains forward–looking statements relating to the Company's strategy, objectives, business development plans and financial position. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company's future financial position, strategy, anticipated investments, costs and results, status and results of clinical trials, size of patient population, plans, outcomes of product development efforts, and objectives of management for future operations, may be deemed to be forward–looking statements. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty or future events or outcomes.
These forward–looking statements involve known and unknown risks, uncertainties, and other factors that may cause the Company's actual results, performance, or achievements or industry results to be materially different from those contemplated, projected, forecasted, estimated or budgeted, whether expressed or implied, by these forward–looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward–looking statements as a prediction of actual results. None of these forward–looking statements constitutes a guarantee of the future occurrence of such events or of actual results. These statements are based on data, assumptions, and estimates that the Company believes are reasonable.
The forward–looking statements contained in this document are made only as of the date hereof. Except as otherwise required by law, the Company expressly disclaims any obligation or undertaking to release publicly any updates of any forward-looking statements contained in this document to reflect any change in its actual results, assumptions, expectations or any change in events, factors, conditions, or circumstances on which any forward–looking statement contained in this document is based.
Contacts:
Media Relations
Vikki Christian
Elixir Health Public Relations
+1 (424) 610-1241
vchristian@elixirhealthpr.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/perseus-holdings-usa-welcomes-ben-bud-m-brigham-to-board-of-directors-301130828.html
SOURCE Perseus Holdings USA
FAQ
Who is Ben 'Bud' M. Brigham?
What impact will Brigham's appointment have on Perseus Holdings?
When was Brigham appointed to the Perseus board?
What is the focus of Perseus Holdings USA?
What companies did Brigham previously lead?
